For research use only
| Cat No. | ABC-SC0012T |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Adipose Mesenchymal Stromal |
| Disease | Normal |
| Storage | Liquid Nitrogen |
AcceGen offers human iPS cell lines derived from Adipose Mesenchymal Stromal Cells.
HighQC™ Human iPSC From Adipose Mesenchymal Stromal Cells is an induced pluripotent stem cell derived from adipose-derived mesenchymal stromal cells (AD-MSCs). The iPS cell line was generated via episomal reprogramming with proprietary vectors encompassing OCT4, SOX2, KLF4, p53 antisense, and EBNA-1. The resulting iPSC lines exhibit typical pluripotent colony morphology, express pluripotency markers such as OCT4, SOX2 and NANOG, exhibit normal and stable genomes, and demonstrate robust trilineage differentiation capacity into the three embryonic germ layers (ectoderm, mesoderm, and endoderm). These iPSCs also maintain a normal and stable karyotype, making them suitable for downstream applications in disease modeling. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human IPSC From Adipose Mesenchymal Stromal Cells, Human iPSC-Adip-MSC, hIPSC-Adip-MSC, Human Adipose MSC Derived iPSC |
| Species | Human |
| Cat.No | ABC-SC0012T |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Adipose Mesenchymal Stromal |
| Disease | Normal |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSCs From Adipose Mesenchymal Stromal Cells serve as a patient-specific in vitro model to study the pathogenesis of systemic sclerosis, particularly its vascular complications. These iPSCs can be efficiently differentiated into endothelial cells to investigate molecular mechanisms underlying vasculopathy, fibrosis, and immune dysfunction. This enables research into disease mechanisms and provides a platform for personalized therapeutic development, including targeted drug screening and potential gene editing studies for vascular dysfunction in systemic sclerosis.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).